-
8m 27sPart 2 | Session 1 EPA in Extreme Cardiovascular Risk: Insights from REDUCE-IT
In this video, Dr Samuel Sherratt provides an overview on the abstract from ACC 2026, 'Rates of Lipoprotein(a) Oxidation Increase at Elevated Levels in a Non-Linear Fashion and Inhibited by EPA'.
Filmed at ACC 2026, these expert-led videos presented by Prof Philippe Gabriel Steg (Hôpital Bichat, Paris, FR) and Dr Samuel Sherratt (Elucida Research & Mount Sinai Fuster Heart Hospital, US) provide a focused overview of contemporary lipid management and cardiovascular risk reduction. They examine residual cardiovascular risk beyond triglycerides, alongside evolving evidence on eicosapentaenoic acid (EPA), including insights from REDUCE-IT and emerging mechanistic data.
Together, the sessions highlight how guideline updates and new evidence can be translated into practical, real-world care.
Learning Objectives
- To summarise the latest recommendations from the ACC/AHA on the use of EPA and fibrates for CV risk reduction in high- and very high-risk patients
- To translate new recommendations with those made on previous European and diabetes guidelines into your daily practice
- To describe how EPA may achieve its clinical benefit outside of TG-lowering
- To list key patient sub-populations who may benefit from EPA
Target Audience
- Cardiologists
- Cardiovascular Specialists
- Endocrinologists
- Internal Medicine
- Lipidologists
More from this programme
Part 1
Managing CV Risk Beyond Triglycerides: Consolidating the Guidelines
This summary consolidates the ACC/AHA, ESC and ADA recommendations on EPA and fibrates for managing cardiovascular risk beyond triglycerides. Prof Philippe Gabriel Steg reviews the underpinning clinical data and guideline differences into practical decision-making.
Part 2
Emerging Insights on the Role of EPA
Faculty Biographies
Samuel Sherratt
Scientific Director
Dr Samuel Sherratt is the scientific director at Elucida Research in Beverly, MA (US). He is also a Visiting Professor at the Mount Sinai Fuster Heart Hospital at the Icahn School of Medicine in New York City, NY.
His research interests include elucidating novel mechanisms of action of omega-3 fatty acids, lipoprotein metabolism, endothelial cell function and disease pathophysiology, and X-ray diffraction analyses to evaluate drug interactions in membranes, among others.
Dr Sherratt has authored or co-authored 29 scientific research and review articles and more than 130 abstracts, which he has presented at national and international cardiology conferences. He received his B.S. in biology from Gordon College in 2015 and his Ph.D. in biochemistry from the University of New Hampshire in 2023.